文章基本信息

标题：Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
本地全文：下载
作者：Xingyue An ; Melisa Martinez-Paniagua ; Ali Rezvan 等
期刊名称：iScience
印刷版ISSN：2589-0042
出版年度：2021
卷号：24
期号：9
页码：1-17
DOI：10.1016/j.isci.2021.103037
语种：English
出版社：Elsevier
摘要：SummaryDespite remarkable progress in the development and authorization of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a need to validate vaccine platforms for broader application. The current intramuscular vaccines are designed to elicit systemic immunity without conferring mucosal immunity in the nasal compartment, which is the first barrier that SARS-CoV-2 virus breaches before dissemination to the lung. We report the development of an intranasal subunit vaccine that uses lyophilized spike protein and liposomal STING agonist as an adjuvant. This vaccine induces systemic neutralizing antibodies, IgA in the lung and nasal compartments, and T-cell responses in the lung of mice. Single-cell RNA sequencing confirmed the coordinated activation of T/B-cell responses in a germinal center-like manner within the nasal-associated lymphoid tissues, confirming its role as an inductive site to enable durable immunity. The ability to elicit immunity in the respiratory tract can prevent the establishment of infection in individuals and prevent disease transmission.Graphical abstractDisplay OmittedHighlights•An intranasal subunit vaccine against SARS-CoV-2 elicits rapid immunity•Stable single-dose vaccine elicits systematic and mucosal immune responses•Spike-specific IgA responses are present in the nasal compartment and the lungImmunology; Virology